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Introduction
Tissue engineered products including naturally derived or 
synthetic biomaterial-based scaffolds with/without autolo-
gous or allogeneic cells are utilized to replace or restore 
the functions of damaged tissues and organs.1 Advanced 
therapy medicinal products (ATMPs) are considered as 
medicines for the treatment of disease or injuries in 
humans using genes, tissues or cells. ATMPs are classi-
fied into categories such as gene therapy medicinal prod-
ucts (GTMP), cell therapy medicinal products (CTMP), 
tissue-engineered medicinal products (TEMPs) and some-
times a combination of these categories.2 In some coun-
tries like the US, a group of biological medicinal products 
are categorized as Human Cells, Tissues, and Cellular and 
Tissue-based Product (HCT/P).1,3 ATMPs have several 
applications in the clinical arena to improve the quality of 
patients life. Organ transplantation is the terminal-stage 
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Abstract
Tissue engineering is an evolving multi-disciplinary field with cutting-edge technologies and innovative scientific perceptions 
that promise functional regeneration of damaged tissues/organs. Tissue engineered medical products (TEMPs) are 
biomaterial-cell products or a cell-drug combination which is injected, implanted or topically applied in the course of a 
therapeutic or diagnostic procedure. Current tissue engineering strategies aim at 3D printing/bioprinting that uses cells and 
polymers to construct living tissues/organs in a layer-by-layer fashion with high 3D precision. However, unlike conventional 
drugs or therapeutics, TEMPs and 3D bioprinted tissues are novel therapeutics and need different regulatory protocols 
for clinical trials and commercialization processes. Therefore, it is essential to understand the complexity of raw materials, 
cellular components, and manufacturing procedures to establish standards that can help to translate these products from 
bench to bedside. These complexities are reflected in the regulations and standards that are globally in practice to prevent 
any compromise or undue risks to patients. This review comprehensively describes the current legislations, standards for 
TEMPs with a special emphasis on 3D bioprinted tissues. Based on these overviews, challenges in the clinical translation of 
TEMPs & 3D bioprinted tissues/organs along with their ethical concerns and future perspectives are discussed.
Keywords
TEMPs, regulations & standards, 3D bioprinting, stem cells, ethical concerns, tissue engineering
Date received: 3 March 2021; accepted: 8 June 2021
1 Tissue Engineering & Additive Manufacturing Lab, Centre for 
Nanotechnology & Advanced Biomaterials, ABCDE Innovation Centre, 
School of Chemical & Biotechnology, SASTRA Deemed University, 
Thanjavur, Tamil Nadu, India
2 Department of Science, Technology and Innovation Studies, School 
of Social and Political Science, University of Edinburgh, High School 
Yards, Edinburgh, UK
3UCL Division of Surgery and Interventional Science, London, UK
*These authors contributed equally to this work.
Corresponding authors:
Deepak M Kalaskar, UCL Division of Surgery and Interventional 
Science, 9th Floor, Royal Free Hospital, Rowland Hill Street, London, 
NW3 2PF, UK. 
Email: d.kalaskar@ucl.ac.uk
Dhakshinamoorthy Sundaramurthi, Anusandhan Kendra – 1, Tissue 
Engineering & Additive Manufacturing (TEAM) Lab, Centre for 
Nanotechnology & Advanced Biomaterials, ABCDE Innovation Centre, 
School of Chemical & Biotechnology, SASTRA Deemed University, 
Tirumalaisamudram, Thanjavur, Tamil Nadu 613 401, India. 
Email: dhakshinamoorthy@scbt.sastra.edu
1027677 TEJ0010.1177/20417314211027677Journal of Tissue EngineeringSekar et al.
research-article2021
Review
2 Journal of Tissue Engineering 
treatment strategy for conditions like myocardial infarc-
tion, acute liver failure, chronic kidney disease, and Type 1 
diabetes, etc. and may replace the need for TEMPs4 
However, shortage of organ donors, high cost and immu-
nological complications limit the affordability and clinical 
success of organ transplantation around the globe.5,6 Thus, 
there is a need for artificial organ fabrication through tis-
sue engineering approaches to overcome the limitations 
of organ transplantation.7 Although various approaches 
have been used to develop engineered tissues, only a 
limited number of TEMPs are approved and commer-
cialized for clinical uses (Table 1). This may be attrib-
uted to the fact that engineered tissues have high risks, 
more uncertainties in safety, efficacy and very expensive 
for commercialization.8
TEMPs are the latest therapeutics that involve one or 
more complex manufacturing processes, varied constituents 
and different characteristic features, which demands unique 
standards and regulations for approval processes.15 Global 
regulatory agencies evaluate the quality, safety, efficacy and 
cost-effectiveness of TEMPs for healthcare applications and 
regulate through various steps involved from commerciali-
zation to clinical practice.8,16 Tissue engineered medical 
products are regulated based on exclusively framed legisla-
tions in different countries. These legislations have the same 
set of objectives and rules but follow different regulatory 
terms/approval processes for commercialization.15
TEMPs submitted under clinical transformation 
approval need to be manufactured in Good Manufac-
turing Facilities (GMP) setup using clinical-grade raw 
Table 1. List of approved tissue engineered medical products (TEMPs) commercialized in various countries.
Product name Description Intended application Year of 
commercialization
Origin
Omnigraft™ Bilayer graft comprising upper silicone layer 
and lower collagen and chondroitin layer for 
chronic diabetic foot ulcers
Skin1,3,9,10 2016 US (United 
States)
ReNovaCell™ Skin autologous (epithelial cell) harvesting 
device as skin graft for vitiligo
2016 Europe
Hyalograft 3D™ Cultured autologous (skin fibroblast) on 
hyaluronic derivative scaffold for diabetic foot 
ulcer
2007 South Korea
Dermagraft® Cultured neonatal dermal fibroblast on 
bioresorbable scaffolds for foot ulcer 
treatment
2001 US
Ossron™ Autologous (bone marrow stem) implantation-







Recombinant human bone morphometric 
protein—2 on an absorbable collagen sponge 
for bone grafting (spine and orthopedic)
2015 US
MACI® Cultured autologous cell source 
(chondrocytes) on porcine collagen scaffold for 
treating damaged cartilage tissue
Cartilage1,11,12 2016 US
Ortho-ACI™ Autologous chondrocytes seeded with the 
scaffold for cartilage defect
2017 Australia
Spherox Human autologous (chondrocyte) spheroids 





JACC® Cultured autologous (chondrocytes) cells on 
collagen for cartilage defect
2012 Japan
Novocart 3D Autologous chondrocytes on 3D collagen 
chondroitin sulfate scaffold for cartilage defect
2003 EU










HeartSheet® Autologous skeletal myoblast derived cellular 




Decellularized ECM based 3D scaffold 
(allograft) for bridging nerve gap
Nerve14 2015 US
Neurotube® Polyglycolic acid (PGA) based mesh tube for 
small pheripheral nerve lesions
1999 US
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materials with defined Quality Attributes (QAs) and also 
need to be tested clinically with Good Clinical Practice 
(GCP) guidance.17 Regulatory authorities of medicinal 
product approval generally focus on the criteria men-
tioned above and more specifically, on its benefits and 
risk involvement.8
In the current decade, TEMPs fabricated through con-
ventional tissue engineering approaches have a wide range 
of potential applications, such as congenital heart disease 
(CHD), heart valve replacement, bone fracture healing, 
severe burn injuries, cartilage defect, acute/chronic liver 
problems, etc., are now considered as a safer and efficient 
clinical solution.4 Figure 1 shows the classification of 
ATMPs with emphasis on TEMPs, which falls under the 
main scope of this review. Further, bottom-up and reverse 
engineering approaches for fabricating patient-specific 
three-dimensional cellular/biomaterial scaffold with 
autologous cells (stem cells/other cells) using 3D bio-
printing technique has become a better strategy in fabri-
cating organs with biomimetic geometries and other 
physiological features of native tissues without any 
immune complications.15,16,18–20 3D printing has greatly 
evolved as an efficient technology especially for various 
applications in regenerative medicine. The progress and 
applications of 3D printing and bioprinting in regenerative 
medicine were broadly represented in Figure 2(a). Hence, 
computerized fabrication of multi-functional human 3D 
organs could facilitate the ease of organ transplantation and 
3D tissue/organ model fabrication for pre-clinical drug/bio-
logical testing in the future (Figure 2(b)).
From the above perspectives, this review mainly 
focuses on all the legislations, regulations, guidelines and 
standards followed worldwide for clinical trial approval 
and commercialization of the tissue engineered products. 
Further, the current tissue fabrication process with the 
advancement of additive manufacturing approaches for 
engineering personalized 3D printed tissues, components 
& types of 3D bioprinting, and the potential of bioprinting 
technology to fabricate tissues/organs for transplantation 
applications are also discussed. Additionally, the charac-
teristics of bioprinted constructs, their applications and 
how they stand in comparison with tissue engineered med-
ical products from an ethical and regulatory standpoint are 
elaborated. Further insights into the regulatory aspects of 
tissue engineered and bioprinted organs/tissues that greatly 
hamper the widespread clinical translations are discussed. 
Additionally, the ethical issues revolving around tissue 
engineered and bioprinted products and challenges in 
commercial success are also discussed. Finally, future per-
spectives of tissue engineered constructs are discussed and 
compared with the projected future of 3D bioprinting in 
regenerative medicine applications.
Figure 1. Schematic representation of components and classification of ATMPs and their applications.
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Tissue engineered medical products 
(TEMPS)
Tissue engineering (TE) is an interdisciplinary field that 
employs the principles of life sciences and engineering to 
restore and regenerate the physiological activity of dam-
aged tissues or organs. This has led to the rapid develop-
ment of tissue engineered medical products (TEMPs) 
using conventional tissue engineering strategies for diag-
nostic and therapeutic applications in various tissues 
such as skin, cartilage, bone, blood vessels, heart valves, 
etc., using components such as cells, scaffolds, biomole-
cules, processed tissues and their derivatives.21 Notably, 
there are several TEMPs for cartilage defects and skin 
substituents which are currently in phase II and III clini-
cal trial stages and so far provided the confirmations on 
therapeutic value, regenerative activity, safety and long-
term biological effects.22,23 Moreover, the increase in 
clinical demands for organ transplantation, specifically 
for aging populations has propelled the exponential need 
for TEMPs on a larger scale and at affordable prices. 
However, limitations in conventional fabrication tech-
niques such as lack of three-dimensional architecture, 
cellular positioning at the desired locations, variable cel-
lular density, template requirement, difficulty in complex 
shape fabrication suggest the usage of advanced fabrica-
tion techniques to engineer tissues or organs for trans-
plantation applications.24,25
Figure 2. (a) Chronological history of 3D printing/bioprinting in potential biomedical applications, (b) imagined future of 3D 
bioprinting—3D models obtained through CT or MRI images and computationally redesigned according to the personalized 
requirements.
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An additive manufacturing approach: 3D 
printed TEMPS
3D printing has now gained huge attention from many 
users of different fields due to the layer-by-layer deposi-
tion, feasibility in fabricating complex models, ease 
of operation, low cost and multi-material deposition.26 
Various 3D printing techniques have been employed to 
develop patient-specific scaffolds and tissues using poly-
mers such as polylactic acid (PLA), titanium, ceramics, 
polycaprolactone (PCL), polyurethane, etc. and most of 
them are evaluated for durability and functionality in 
both in vitro and in vivo studies for tissues such as bone, 
heart valves, skin, intestines, etc.27 Currently in clinical 
surgery, 3D printing technology plays a major role by pro-
viding different technical and visual or physical support in 
the form of pre-operative surgical guides (cutting/drilling/
planning), surgical tools, custom specific implants and 
prostheses.28 3D printing offers a wide range of materials 
selection approach to create 3D structures as support or 
major implant for spinal surgery, maxillofacial, cranial, 
dental, orthopedic surgery, etc. Undoubtedly, for all these 
surgical approaches, medical surgeons collaborate with 
additive manufacturing based medical device companies 
or bioengineers to assist in the design and 3D printing for 
specific requirements. Additionally, 3D planning soft-
ware makes patient-specific virtual surgery model to pro-
vide the clear-cutting plane and drilling trajectories to 
limit damages for nerves and blood vessels and improves 
positioning accuracy to place the implant.29 Subsequently, 
the printing of different sized models can help to over-
come the limitation of using cadaver-based surgical 
planning where specificity and availability are a major 
issue.30
In a recent study of tissue regeneration to mimic native 
tissue structure, 3D printed bone graft made from PCL 
impregnated chitosan loaded with rabbit bone marrow 
stem cells showed improved differentiation activity and 
increased expression of osteogenic specific genes such as 
alkaline phosphatase (ALP), collagen type I (COL1), oste-
ocalcin (OCN), and Runt-related transcription factor 
(RUNX2) after 14 days in vitro. This graft was also subcu-
taneously implanted in nude mice and observed that the 
3D printed scaffold exhibited stronger osteogenesis and 
bone-matrix formation after 3 weeks of surgery.31 Similarly, 
Zhang et al. have developed 3D printed navigational tem-
plate using Computer Aided Design (CAD) software to 
facilitate the localization of small peripheral lung nodules 
and reduces the radiation exposure for lung cancer patients 
(ID: NCT02952261). The results of about 200 patients 
demonstrated that the personalized 3D printed template 
guided percutaneous localization was achieved with better 
accuracy and omits computed tomographic (CT) analysis 
during treatment.32
3D bioprinting of tissues and organs
3D bioprinting technique is a 3D tissue fabrication tech-
nique where the cells are integrated into a cross-linkable 
hydrogel matrix called bioink to create 3D tissue equiva-
lent constructs in the desired pattern.33,34 3D bioprinting 
requires essential components such as 3D imaging, CAD/
CAM software, bioink, and bioprinter to carry out the fab-
rication process. Bioink is a combination of cells, poly-
mers (biomaterials) and signaling molecules like growth 
factors with adequate viscoelastic and cell supportive 
functionalities that are suitable for the printing of tissues 
and organs in a bioprinter platform.35 Further, the develop-
ment of novel biomaterials or chemical modification of 
existing materials helps to customize bioinks for tissue-
specific applications. Moreover, bioinks are deposited in a 
layer-by-layer manner at desired locations to enable the 
fabrication of vascularized 3D structures for tissue or 
organ regeneration applications. Bioink made of fibrous 
proteins such as collagen and fibrin contains more than 
90% water, allowing them to create cell supportive and 
biocompatible tissue constructs.36 Natural polymers such 
as collagen, Matrigel, gelatin, alginate, agarose, methyl-
cellulose, fibrinogen and synthetic polymers such as 
pluronics, carbopol, nanoclay, hydroxyapatite and poly(N-
isopropylacrylamide) have been used as bioinks for the 
fabrication of various tissues like cardiac patches, bone, 
cartilage, and cornea.37 Bioprinters capable of achieving 
ideal print speed, human-scale resolution, and also 
equipped to operate multi-material print heads could be 
beneficial in the fabrication of patient-specific tissues or 
organs. Bioprinting is divided into three types based on the 
bioink dispensing mechanism such as inkjet bioprinting, 
laser-assisted bioprinting and extrusion-based bioprinting. 
Inkjet bioprinting requires less viscous bioinks to dispense 
through micron-sized nozzles either by thermal or piezoe-
lectric stimulus (Figure 3).38 Laser-assisted bioprinting 
methods employ focusing the laser pulse on the metal-
coated plate with low—medium viscosity bioinks to create 
3D tissues (Figure 3).39 These two printing systems have 
good printing resolution (20–40 µm) and cell viability 
(>90%). However, these methods are not widely preferred 
for fabricating human scale 3D tissues due to the difficul-
ties in layer-by-layer stacking ability beyond a particular 
build volume. Extrusion bioprinters can dispense a 
variety of bioinks with a wide range of viscosities either 
through pneumatic or mechanical screw-based mecha-
nisms (Figure 3). In recent years researchers have success-
fully fabricated various 3D tissues and organ models as a 
proof-of-concept using extrusion bioprinting.40
Further, the features and limitations of these various 
bioprinting techniques such as inkjet, extrusion and 
laser-assisted bioprinting methods are briefly tabulated 
in Table 2. Printing of multiple cell types with variable cell 
6 Journal of Tissue Engineering 
Figure 3. Schematic representation of different types of bioprinting. (a) Inkjet bioprinting, (b) laser-assisted bioprinting and  
(c) extrusion bioprinting.
Table 2. Comparison of different techniques utilized in 3D bioprinting of tissues.
Inkjet bioprinting Laser-assisted bioprinting Extrusion bioprinting
Contact Non-contact Non-contact Contact
Dispensing form Droplets Droplets/continuous deposition Filament
Dispensing mechanism Thermal and piezoelectric Laser Pneumatic or mechanical
Printing speed 1–10,000 droplets/s 1–2000 mm/s 0.1–150 mm/s
Viscosity <10 mPa s 1–300 mPa s 30–1 × 106 mPa s
Resolution 20–100 µm 40–100 µm 40–1200 µm
Materials used as 
bioinks
Alginate, gelatin, collagen 
type I, fibrin, polyethylene 
glycol (PEG) and gelatin 
methacrylate, etc.
Alginate, collagen type 1, gelatin, 
fibrin, etc.
Alginate, gelatin, gellan gum, guar 
gum, methylcellulose, collagen 
type 1, matrigel, fibrinogen, 
collagen methacrylate, 
gelatin methacrylate, elastin, 
polycaprolactone, polyethylene 
glycol, polyvinyl alcohol, 
polyvinyl acetate, etc.
Cell viability ⩾85% ⩾90% 60%–90%
Fabrication level Cells and tissues Cells and tissues Cells, tissues and organs
Printed tissues Cardiac, liver, muscle, and 
bladder
Bone, cardiac, skin, cornea and 
nerve, etc.
Cardiac, pancreas, bone, skin, 
intestine, liver, kidney, and 
nerve, etc.
Advantages Fast and cost-effective Cytocompatibility, single-cell 
and multiple cell types printing
Printing of viscous materials, 
the printing of multiple cell 
types, and ease of 3D structures 
fabrication
Disadvantages Clogging, non-uniformity in 
droplet size and difficulty 
to dispense viscous 
materials
Low efficient to form 3D 
structures, unable to dispense 
viscous materials and 
affordability
Low resolution, needle clogging 
and shear-induced cell death
References Derakhshanfar et al.42  
and Ding et al.43
Koch et al.44 and  
Guillotin et al.45
Lee et al.46 and Gaetani et al.47
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densities (1 × 106 cells/mL to 1 × 108 cells/mL) at desired 
locations made 3D bioprinting one of the most advanced 
techniques for tissue or organ fabrication.41 A comprehen-
sive literature review of 3D tissues/organs fabricated using 
different bioprinting strategies for tissue regeneration 
application has been tabulated in Table 3.
Regulatory roles and responsibilities 
of approving authorities
The main goal of regulatory agencies is to produce laws 
and regulations by following different regulatory frame-
works to allow safer medicinal products for clinical trials 
and marketing purposes. Globally tissue-based products 
(TEMPs) are identified differently based on the categoriz-
ing condition for the regulatory approval. Likewise, 
TEMPs have been considered as drugs in the EU, a medi-
cal device in Japan and biologic/combined products in the 
U.S through their regulations/directives and further their 
approval pathways are decided by assessing the quality, 
safety and efficacy through nonclinical and clinical 
studies.3,12,64 The regulatory agencies of different coun-
tries that deal with clinical trial approval and permission 
for commercialization are listed in Table 4.
Identically, Gene and Cell-based Therapies (GCTs) 
regulatory frameworks are outlined to assess product char-
acteristics, evidentiary and non-evidentiary reasons for 
approval and post-marketing risk management studies.8 It 
is identified that clinical translation of products is approved 
based on confirmed evidential benefit results for US and 
EU applications while regulations of Japan follow non-
confirmed beneficial results. US, EU and Japan regulatory 
agencies are now approving Gene and Cell-based Therapies 
(GCTs) with scientific uncertainties and safety risks to 
allow the clinical transformation based on medical needs.8 
Oftentimes, approval processes for new products are based 
on the standards available on the technical details of pre-
existing relevant products.
PROVENGE was the first commercialized cell therapy 
treatment for prostate cancer treatment in the United States 
and Transcyte for third degree skin replacement graft was 
the first FDA approved tissue graft in 1997.12 Activskin, a 
skin graft was the first approved TEMP in China by 2013.15 
In 2001, the first cell therapy and tissue engineered prod-
uct (chondrocyte-based product) was successfully com-
mercialized in South Korea. Relatively, South Korea has 
more number of cell therapies in clinical practice as on 
2018 status.1 Totally 10 ATMPs were approved by the 
European Medicines Agency (EMA) in the Europe Union 
and likewise, the first commercialized tissue engineered 
product in Europe is ChondroCelect (for treating cartilage 
defects) in 2009, but this product was discontinued in 2016 
due to commercial reason from its marketing authorization 
TiGenix NV.12 As discussed earlier, in comparison with the 
last decade, more tissue-based therapies are approved by 
the authorities in consideration to produce these high ther-
apeutically efficient TEMPs for the unmet medical needs.10 
As a result, several products for skin, cartilage, bone, 
heart, neural and several other complex organs have been 
commercialized in recent times.
Current regulations for TEMPs
Recently updated tissue engineered product regulations, 
approval requirements and rules enforced so far in U.S, 
India and European Union for the currently available 
TEMPs are shown in Table 5.
US based regulations. Unites States (US) authorized Food 
and Drug Administration (FDA) is a regulatory agency, 
which enforces Food, Drug and Cosmetic Act (FDCA), 
Kefauver-Harris Amendments, Medical Device Amend-
ments and Public Health Service Act (PHS) for rules and 
conditions to evaluate product safety and efficacy in the 
United States of America (USA) medical care.68 In this 
current decade, to utilize the safer health care innovations 
with an involvement to technically advance innovative 
medicinal therapy, several expedited approval pathways, 
alternative pathways with exemptions and special situation 
based decisions have been structured and enacted into leg-
islations for further approval at a short period of time.69 
Recently FDA guidance expedited program includes Fast 
Track designation and Breakthrough Therapy designation 
were created through regenerative medicine advanced 
therapy (RMAT) designation program by 21st Century 
Cures Act for the sponsors of regenerative medicine 
products.12
The regulatory criteria for human cells, tissues, and cel-
lular & tissue-based products (HCT/P) issued by the FDA 
of the US are followed by the Center for Biologics 
Evaluation and Research (CBER) under section 361 of the 
Public Health Service Act (PHS) provided in 21 CFR (Code 
of federal regulations) Parts 1270 and 1271 regulations.3 
Additionally, for some HCT/Ps not found in the mentioned 
criteria of 1271.10(a), it could be regulated as drugs, 
devices or biologics under section 351 of the Public Health 
Service Act (PHS) and Federal Food, Drug, and Cosmetic 
Act (FD&C 23Act).70 Due to the interdisciplinary land-
scape, HCT/Ps products with some exemptions such as 
cryopreserved femoral vein for AV shunt, cultured cells 
on biomaterial/decellularized scaffolds are regulated as a 
medical device with tissues or combination products 
through Center for Devices and Radiological Health 
(CDRH).71 These regulations include HCT/P criteria for 
minimal manipulation (possibilities of processing method 
to induce alteration characteristics of the cells or tissue to 
replace/restore the function), homologous usage (without 
the combination of other articles which could give rise to 
new clinical application), its ability of with or without 
systemic effect having a dependency on cells metabolic 
8 Journal of Tissue Engineering 

















from the sciatic 
nerve
⩾89% Schwann cell incorporated 
constructs showed good viability, 
elongation and directional growth 
of neurites in the longitudinal 
axis of strands and supported 














– Nanoparticles-in-hydrogel nerve 
conduit that releases drug 
to facilitate peripheral nerve 
regeneration via Hippo pathway
Tao et al.49
Intestine Collagen type-I Vertically moved 
3D printing
Caco-2 cells 90% Cell laden collagen/SIS villi showed 
significant cell proliferation, 
glucose uptake, tight-junction 
















90% Bioprinted skeletal muscle tissue 
exhibited organized multi-layered 
muscle bundles with aligned 
myofiber-like structures showed 
82% of functional recovery in a 
rodent model 8 weeks of post-
implantation
Kim et al.51












The hybrid 3D cell printing system 
has extrusion and inkjet modules. 
Printed structures showed dermis 
and stratified epidermis layers after 
14 days in vitro
Kim et al.52










adipose stem cells 
(hASC)
⩾92% The hASC-laden β-TCP composite 
structure showed significant 
osteogenic gene expression levels
Kim and Kim53






– In situ printing of HUVECs 
improved vascularization and bone 













– Printed constructs displayed 
17.2% surface area covered with 
proliferating chondrocytes after 
60 days of culture in vitro
Apelgren 
et al.55















– Alginate/gelatin bioink with hECM 
enhances cell viability and liver-
specific metabolic activities
Hiller et al.56








75% Printed GelMA patch with dECM 
have shown better proliferation, 




















82% Laser printing does not affect the 
pluripotency, differentiation and 
proliferation ability of iPSC
Chichkov 
et al.58









cells and human 
adipose-derived 
stem cells (hASC)
– Successfully used laser bioprinting 
for corneal applications using 
human stem cells and showed 
layered 3D bioprinted tissues 
mimicking the structure of native 
corneal tissues
Sorkio et al.59
Cornea Gelatin, alginate 







⩾94% The bioprinted cells showed good 
cell proliferation and expression 
of cytokeratin 3 (CK3) with the 











86% This double gelation mechanism 
and developed constructs showed 
good layer stacking ability and it 
















⩾80% GelMA/alginate blended bioink 
exhibited good biological 
characteristics that supported 
the spreading and proliferation of 













– Agarose/collagen hydrogel blend 
can be 3D printed and printed 




Table 4. List of regulatory agencies authorized in various countries for medicinal product regulation.
Regulatory agency Country
FDA’s (Food and Drug Administration)—established Center for Devices and Radiological 
Health (CDRH) for medical device regulation, Center for Biologics Evaluation and Research 
(CBER) and Center for Drug Evaluation and Research for drug regulation
USA
Pharmaceuticals and Medical Device Agency (PMDA) and Ministry of Health, Labor and 
Welfare (MHLW)
Japan
European Medicines Agency (EMA) Europe
Ministry of Health and Family Welfare, Central Drug Standards Control Organization, 
Indian Council of Medical Research
India
Ministry of Health of the Russian Federation Russia
State Food and Drug Administration (SFDA) China
Department of Health, Health Protection Agency, Medicines and Healthcare Products 
Regulatory Agency
United Kingdom
Ministry of Health, National Institute of Pharmacy and Medicines, National Authority of 
Medicines and Health Products
Portugal
Ministry of Social Affairs and Health, Finish Medicines Agency Finland
Korean Food and Drug Administration (KFDA) South Korea
Table 3. (Continued)
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activity.70 Moreover, this can also regulate the usage of 
only FDA-registered resource materials for medical appli-
cation. Further, it also states that manufacturers of HCT/P 
should register and list the product for approval from the 
authorities for the license, permission of preclinical, clini-
cal data approval evaluation (Table 6). To facilitate updat-
ing, electronic submission is also possible using electronic 
HCT/P establishment registration (eHCTERS) system 
with all the submission of requirements.
FDA is also providing special protocol assessment 
(SPA) guidance by the Center for Drug Evaluation and 
Research (CDER) and the Center for Biologics Evaluation 
and Research (CBER) to help in study designs animal 
studies and clinical studies and trials. Under section 505(b)
(5)(B) of the FD&C Act, under SPA, drug stability or ani-
mal efficacy protocols should apply for approval with 
study designs and statistical analysis. Submission of SPA 
request is a process that involves (i) Informing FDA of an 
upcoming request; (ii) Timing of a request for review pro-
cess up to 45 days which includes documents submission 
and resubmission of additional required documents; (iii) 
The request format should contain the cover letter with 
bold block letters mentioning “REQUEST FOR 
SPECIAL PROTOCOL ASSESSMENT”; (iv) The SPA 
should submit to the appropriate CDER or CBER division, 
using standard or electronic submission. FDA will start 
analyzing the submissions to see whether it is suitable 
under SPA and communicate decision by mail within 
45 days of the review timeline.74
EU based regulations. In the EU (European Union), classi-
fication of tissue engineered products are clearly explained 
and regulated well and Regulation (EC)No 1394/2007 
was designed and amended on December 30, 2008 for 
Advanced therapy and medicinal products (ATMP includ-
ing cell therapy, gene therapy and tissue engineered medic-
inal products) for evaluation of product quality, efficacy 
and safety.17,75 Product description, scientific and technical 
requirements for improved quality, safety and efficacy are 
followed through Directive 2001/83/EC, which states that 
cells are considered to be engineered if it is manipulated 
including cutting, shaping, centrifugation, sterilization 
procedures, cryopreservation, lyophilization, etc. Like-
wise, Directive 2004/23/EC and Directive 2001/20/EC, 
Regulation (EC) No 726/2004, Directive 2005/28/EC, 
2003/94/EC are followed by European Medicines Agency 
(EMA) for marketing authorization requirements and reg-
ulation procedure.76 These directives state that the appli-
cants producing product specifications should provide the 
product details clearly including, name, composition, 
quantitative & qualitative details, clinical particulars, its 
interaction with other substance & molecule, precautions 
steps if any, usage during pregnancy & lactation details, 
pharmacological, pharmacodynamics & pharmacokinetic 
properties, pre-clinical safety data, shelf life, storage con-
dition and its procedure, marketing details, etc. In addition, 
packaging should mention the marketing authorization, 
manufacture batch number 2004/23/EC, expiry date, 
method of use, special warnings, etc.76 Further, all the clin-
ical data analysis, proper GMP and GLP activities are 
expected. Particularly, conditional approval has been 
described by the regulation (EC)N 507/2006 with some 
difference in the regulatory framework of EU.17 EU regu-
latory implements adaptive approach regulatory pathways 
mostly for the cellular and tissue-based products. Besides, 
other pathways are also there such as standard pathway, 
conditional pathway, adaptive licensing and PRIority 
MEdicines (PRIME) are framed to regulate products of 
different categories.8,12
India based regulations. In India, Drug and Cosmetic Act 
1940 and Rules 1945 were enacted to regulate drug 
approval by Central Drugs Standard Control Organization 
(CDSCO).66 Especially Cell Biology Based Therapeutic 
Drug Evaluation Committee (CBBTDEC) by CDSCO was 
formed in 2010 for cell therapy related clinical approval.77 
Additionally in India, the Indian Council of Medical 
Research (ICMR) involve in providing guidelines for con-
ducting biomedical and clinical research activities for clin-
ical regulation. Briefly, the Drugs & Cosmetics Act 1940 
was legislated by Indian law in concern with the import-
ing, manufacturing and marketing drugs and cosmetics 
Table 6. Regulations and process details of FDA based Center for Biologics Evaluation and Research (CBER)72,73.
FDA approval process Functions
Investigational new drug (IND) or device 
exemption (IDE) Process
Request FDA to grant permission to administer drug/medical 
products to humans
Expanded access to experimental biologics Request access for the use of non-FDA approved medical products
Biologics license application (BLA) process Request to obtain a license by a manufacturer or an applicant before 
marketing after submitting manufacturing methods, pre-clinical and 
clinical data for evaluating safety, quality and efficacy
Premarket notification (510 k) process Submission to FDA to demonstrate the efficacy and safety of the 
product to market it
Premarket approval (PMA) process Process of FDA to evaluate the safety and efficacy of the approached 
medical product (mostly Class III medical devices)
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commercially to all over India with assured safety and 
high quality in their role. In accordance with this act, 
CDSCO has established Drugs Technical Advisory Board 
(DTAB) and Drugs Consultative Committee (DCC) with 
the main objective to maintain and follow common stand-
ards in commercializing, clinically practicing the new 
drug/existing drug for human disease treatment. Tissue 
engineered products including stem cell-based products 
are categorized as a drug in evaluating its clinical practice 
application, regulation and for its clinical practice by 
CBBTDEC. Importantly, requirements governing the clin-
ical trial approvals, license and permissions are covered 
under the Schedule Y, Rules 122 A, 122 B, 122 DA, 122 
DB, 122 DAC, 122 DD.66 Product safety and efficacy is 
evaluated through the Chemistry, Manufacturing and Con-
trol (CMC) data, pre-clinical data and clinical trial data 
(phase I, phase II, and phase III). Moreover, ICMR had 
launched ethical guidelines for biomedical research on a 
human subject in 2000 (revised in 2006 and 2017) and 
good clinical laboratory practice guidelines (2008) for the 
conduct of clinical trials in India.77 Good clinical practice 
(GCP) guidelines provide standards for obtaining quality 
data by designing reproducible clinical work protocol in 
the research laboratories to obtain the same quality, relia-
ble results, meanwhile saving money, time and complexity 
involved in experiments.
Regulations followed by other countries. Likewise in Japan, 
Pharmaceuticals and Medical Devices Agency (PMDA) 
regulates the tissue engineered products to clinical prac-
tice through the Safety and Regenerative Medicine Act 
(RM Act) and Pharmaceuticals, Medical Devices and 
Other Therapeutic Products Act (PMD Act).78 In China, 
Tissue Engineered Medical Products (TEMP) are regu-
lated through different categories as class III medical 
device based on the classification mentioned in the Medi-
cal Devices Classification Rule (MDCR, CFDA Order 
No. 15) by China Food and Drug Administration(CFDA).15 
In China, the regulatory approach is mainly focused on 
the final product utility in treating the medical need and it 
does not mainly depend on the raw material and process-
ing method.
A cohort study conducted by Coppens on the approval 
of GCTs between 2008 and 2017 by US, EU and Japan 
regulatory concluded that Japan showed higher acceptance 
of GCT in consideration with uncertainties and safety risks 
followed by EU and US. In the majority of cases, unmet 
medical needs are considered for its regulatory approval 
by the EU and Japan clinical transformation regulatory 
system. While considering post-marketing characteristics, 
product safety, quality and risks are analyzed in Japan and 
EU, but in US safety is the main focus.8 However, US and 
EU have many alternative pathways and regulations to 
facilitate the approval process relatively faster. Japan fol-
lows time limited approval pathways to overcome some of 
the already existing limitations.64
Regulations for 3D printed/bioprinted TEMPs
3D printed (additive manufactured) products in medical 
applications are fabricated as whole device/part which 
could be utilized as prosthesis or an implant or other medi-
cal assistance devices.73 In recent times, 3D printed pros-
theses for hip, knee, skull, jaw bone or joint implant, limb 
prostheses, orthopedic implants, heart valves, etc., are 
developed and currently under extensive clinical research. 
These 3D printed prostheses have the potential to create 
personalized implants of complex structures with pre-
cisely controlled material and structural properties within 
short time when compared to other implant fabrication 
methods.2,53,79,80 Further, additive manufactured metal 
implants have added advantage in controlling internal 
porous structures to promote biological fixation with 
long-term stability. Although 3D-printed implants (includ-
ing metal implants) are devoid of cellular materials, they 
are also regulated as medical devices.81 However, bio-
printed TEMPs with complex cell source and bioink com-
position for regenerative medicinal application could be 
regulated either as biologics or drugs/medical devices 
based on the regulatory authorities.82 3D bioprinted tissues 
fall between the categories of living materials & technol-
ogy and hence do not fall directly into the existing catego-
ries of regulations. In order to bring this to light, experts 
have developed a concept called “bio-objects,” which 
means that all kinds of biotechnologies fall “in-between” 
the existing categories of living and non-living matter.83,84 
These “bio-objects” do not fall into the standard regula-
tory frameworks which are based on the clinically well-
established medicinal product categories. Consequently, 
these products require new regulations/laws for clinical tri-
als and commercialization.
In the US, personalized 3D printed medical devices are 
regulated under the medical device category or with some 
custom device exemptions to evaluate their safety and 
efficacy through pre-market/post-market requirements.85 
However, generic medical devices are categorized into 16 
special domains (based on their usage and risk) and each 
device is considered among one of the three regulatory 
classes based on its safety level and efficacy. These medi-
cal devices are classified through de novo classification—
a risk-based classification for the regulations as mentioned 
in Table 7. Based on these categorical classifications, 
510 k regulation is required for class I and II devices while 
for class III, premarket approval application (PMA) is 
required for the FDA approval process. All these classifi-
cation systems are subject to common control require-
ments of Food, Drug and Cosmetic Act (FDCA) and 
additional market approval as a design control model from 
regulatory agencies.69
The FDA has provided guidelines for the 3D printed 
materials under two different considerations such as 
Design and Manufacturing Considerations (device design/
patient match design, software process, material, printing 
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process & control, post-process and validation) and Device 
Testing Considerations (device description and measure-
ments, material characterization and mechanical testing) 
to ensure product quality, efficacy and determination of 
classification for regulations.88 Currently, 3D printed 
medical devices are regulated through premarket noti-
fication, New Drug Application (considering as new 
drug) and Biologics License Application (considering as 
biologics).73 The FDA has so far approved the AXIOM 
20 3D printer for manufacturing medical devices and one 
3D printed drug named Spritam® tablets for epilepsy 
treatment.89
On the other hand, EU follows legislation such as 
AIMDD 90/385/EE (Active Implantable Medical Device 
Directive), MDD 93/42/EEC (Medical Device Directive) 
and IVDMDD 98/79/EC (In Vitro Diagnostic Medical 
Device Directive) for 3D printed medical device products. 
Further, as per the standards mentioned in directive 93/42/
EEC, medical devices are classified into four categories 
such as Class I (Noninvasive devices), Class IIa, Class IIb 
and Class III ranked from lowest to higher risk (Table 7). 
Higher rank classes require higher safety assessment lev-
els and such classification levels are decided based on the 
consideration of patient contact duration, degree of inva-
siveness and place of the implantation/contact in human 
body part. These rules have been followed by effectively 
implementing as a set of 18 rules presented in Table 8. A 
titanium based (Ti-6Al-4V) 3D printed implant called 
iFuse-3D is clinically used as structural support for sac-
roiliac joint to promote bone growth. This implant has 
received market clearance under conventional medical 
devices regulations in both US and EU. Post-market 
evaluation of this implant has assessed patient safety and 
efficacy of the product similarly to a machined implant. 
The clinical outcomes had revealed that iFuse-3D reduced 
the pain related complaints, thereby avoided secondary 
corrective surgeries. In addition, this implant did not show 
any unanticipated clinical complaints after treatment and 
hence is efficient in creating patient-specific implants 
using 3D printing technology.90 Likewise, Ackland et al. 
fabricated personalized 3D printed prosthetic temporo-
mandibular joint (TMJ) for a 58-year female patient. This 
prosthetic was modeled using patient musculoskeletal 
modeling for assessing implant stress and strain, applied 
load, screw stress and other physiological loadings. 
Further, the modeled prosthetic was analyzed, fabricated 
and finally implanted into the patient to study its efficacy. 
It was observed that a normal jaw opening distance of 
40.0 mm was achieved with less pain after 6 months of 
postoperative surgery. These results demonstrate the 
effectiveness of personalized 3D printed complex joint 
replacement prosthetics developed through several mod-
eling and computational analysis.91 Hyun Ho Han et al. 
have fabricated patient-specific, 3D printed biodegrada-
ble scaffolds using medical-grade polycaprolactone and 
implanted them in three patients with complex maxillary 
defects. This implant is registered as a medical device in 
South Korea (registration No. 14–1337) and manufac-
tured according to Good Manufacturing Practice provi-
sions (registration No. KTC-ABB-170177). In the 
follow-up period of 16 months, implanted scaffolds pro-
moted neo-tissue ingrowth which was confirmed by CT 
images compared between pre and post-surgery images 
(2711 mm3) and Hounsfield unit values (preoperative - 
−76.269; after 6  and 16 months of implantation - +63.7825 
and +73.0488).92
Table 7. Classifications of medical devices (TEMPs) based on risk levels.
US—medical device86
Class I—General control 
(with/without exemptions)
Class II—General control and specific control (with/without 
exemptions)
Class III—General control 
with premarket approval
•• Low risk
•• For example, breast 
pump, stethoscope, etc.
•• Moderate risk device
•• For example, catheter, bone plate, joint implant, etc.
•• Highest risk devices
•• For example, Mechanical 
heart valve, implantable 
infusion pump, heart 
stent, hip prostheses, etc.
EU—medical device87
Class I Class IIa Class IIb Class III
•• Low risk
•• Noninvasive device
•• For example, 
stethoscopes, electrodes 
(EEG/ECG), etc.
•• Low to medium risk
•• Surgically invasive/
noninvasive, active and 
nonhazardous to patient
•• For example, infusion 
cannula, surgical swabs, 
needle for suturing, etc.




•• (Has some hazardous 
effect)
•• For example, catheters, 
peripheral vascular graft 
and stent, maxillofacial 
implants, etc.
•• High risk
•• Supports human life in 
direct connection with 
health system
•• For example, 
Neuro-endoscopes, 
cardiovascular catheter, 
biological heart valve, etc.
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Table 8. EU directives and classification rules for medical devices as per annexure IX of directive 93/42/EEC87.
Category Rules Indications Medical device class category
Non-Invasive Rule 1 Do not touch patient/contact only skin Class I
Rule 2 Channeling or storing for eventual 
administration
Class I
Class IIa (if it is used with blood or used along with 
active device of class IIa and higher classes)
Rule 3 Modify biological or chemical 
composition of blood, body fluid, etc. for 
infusion
Class IIb
Class IIa (only filtration, centrifugation, or gas 
exchange)
Rule 4 In contact with injured skin Class I
Class IIa (intended to manage micro environment of 
skin)
Class IIb (intended for wounds which breach dermis 
and needs secondary intent for healing)
Invasive Rule 5 Invasive in body orifice or stoma (not 
surgically invasive)
Class I (transient use, sort term use only in oral cavity/
ear canal/nasal cavity)
Class IIa (short term use, connected to active medical 
device in class IIa and higher device, long term use in 
oral cavity/ear canal/nasal cavity)
Class IIb (long term use)
Rule 6 Surgically invasive
Transient use
Class I (reusable surgical instrument)
Class IIb (supply energy/ionizing radiation, biological 
effect mainly/wholly absorbed, intended to administer 
medicine in a potentially hazardous manner)
Class III (to monitor/control/diagnose/correct defect 
in heart or central nervous system (CNS) by direct 
contact
Rule 7 Surgically invasive
Short term use
Class IIb (supply energy/ionizing radiation, undergo 
chemical change in body or administer medicines)
Class III (to monitor/control/diagnose/correct defect 
of heart or central nervous system (CNS) by direct 
contact)
Rule 8 Surgically invasive
Long term use and implantable device
Class IIa (placed in teeth)
Class III (in direct contact with heart or CNS, 
biological effect or mainly absorbed, undergo chemical 
change in body or administer medicine, breast implant, 
hip, knee and shoulder joint replacement
Active 
devices
Rule 9 Active therapeutic devices intended to 
administer or exchange energy
Class IIa
Class IIb (if it is hazardous way, intended to control/
monitor/influence directly the performance of class IIb 
active therapeutic devices)
Rule 10 Active device for diagnosis, is intended 
to supply energy, to image in vivo 
distribution of radiopharmaceuticals or 
for direct diagnosis or monitoring of 
vital physiological process
Class IIa
Class IIb (intended to monitor vital physiological 
parameters where variations could result in immediate 
danger, all devices emitting ionizing radiations and 
intended for diagnostic and therapeutic interventional 
radiology
Rule 11 Active devices to administer or remove 
medicines and other substances to or 
from the body
Class IIa
Class IIb (if it is in a potentially hazardous way)
Rule 12 All other active devices Class I
Special rules Rule 13 Device incorporating integral medicinal 
substance liable to act in ancillary way on 
human body
Class III
Rule 14 Device used for contraception or 
prevention of sexually transmitted 
diseases
Class IIb
Class III (if implantable or long-term invasive)
 (Continued)
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Category Rules Indications Medical device class category
Rule 15 Specifically, to be used for disinfecting 
medical devices
Class IIa
Class IIb (specifically to be used for disinfecting invasive 
devices, disinfecting, cleaning, rinsing or hydrating 
contact lenses)
Rule 16 Devices intended for recording of X-ray 
diagnostic images
Class IIa
Rule 17 Device utilizing non-viable animal tissues 
or derivatives (not devices in contact 
with intact skin)
Class III
Rule 18 Blood bags Class IIb
Table 8. (Continued)
Universal standards for tissue 
engineered products
Standards for TEMPs are established to ensure product 
characteristics and all associated analytical procedures to 
ensure common quality results worldwide with improved 
repeatability and reliability of the data. The International 
Organization of Standards (ISO) and the American Society 
for Testing and Materials (ASTM) International are the 
recognized organizations for presenting standardization of 
biomaterials and medical devices.93 ASTM International is 
an organization that provides resources, technical exper-
tise to develop universal standards and guidelines for a 
wide range of developing fields. It comprises several 
committees and subcommittees with respect to specific 
technical areas to frame the standards and guidelines 
including material characteristics, test methods, system, 
etc. Specifically for tissue engineered medical products, 
the F04 committee on “Medical and Surgical Materials 
and Devices” with other subcommittees named Division 
IV “Tissue-Engineered Medical Products (TEMPs)” was 
established in 1997 and the up to date standards published 
by these committees (Table 9).94 Further, ASTM has estab-
lished the F42 committee on “Additive Manufacturing 
Technologies” in 2009 with eight technical committees to 
formulate standards for 3D printed medical products.89
Similarly, ISO comprises a Technical Committee (TC) 
and Sub Committee (SC) to provide standards and guide-
lines for different fields. In particular, for fields of tissue 
engineering and regenerative medicine, technical commit-
tee 150 “Implants for surgery” with subcommittee SC7 
“Tissue-engineered medical products,” which was estab-
lished in 2001 covers TEMPs based on published stand-
ards (International organization of standards/Technical 
committee/Subcommittee ISO/TC 150/SC7) (Table 10). 
Other technical committees such as TC194 (Biological 
and clinical evaluation of medical devices), TC210 
(Quality management and corresponding general aspects 
for medical devices), TC212 (Clinical laboratory testing 
and in vitro diagnostic test systems), TC261 (Additive 
manufacturing) and TC266 (Biomimetics) are established 
with several standards which are widely utilized for health 
care applications.124 Periodically, each committee could 
establish the new standards or revised version of published 
standards for evaluation. For example, TC150 has pub-
lished 165 standards and TC 194 has published 32 ISO 
standards in 2020. An informative list of ASTM and ISO 
standards followed by world regulatory authorities for 
commercializing medical products are tabulated (Table 
11). These standards and updated protocols could help to 
establish a uniform approach and assessment procedure 
for validating medical products including tissue engineer-
ing products while ensuring high quality and more safety 
to humans.115 This is imperative because cellular and acel-
lular synthetic/natural constructs need specific standards 
for characterization and in vitro, in vivo and clinical trial 
analyses with respect to the raw material used.114
TC 261 published ISO/ASTM 52910:2018 standard 
“Additive manufacturing—Design—Requirements, guide-
lines and recommendations,” which describes the design 
consideration that needs to be taken while manufacturing 
different types of products or components through the 
additive manufacturing approach. This standard will pro-
vide necessary guidance to the engineers and students to 
carry out the basic design of additive manufactured prod-
ucts for clinical translation. These design guidelines facili-
tate the manufacturers to decide on optimal cost, quality 
and delivery time. Further, this could also be applied to 
identify the potential of additive manufacturing techniques 
by assessing the choice of material, its availability, build 
volume and print volume comparison.125
ISO in liaison with the governmental, non-governmen-
tal and international organizations have also been facili-
tated to further raise the standards with more expertise in 
the field. For instance, ISO 261 and ASTM F47 have 
jointly framed general standards (framing additive manu-
facturing requirements, guidelines, safety, definition and 
concepts) and specific/broad category of material based 
standards (framing material, process or application 
details) to continuously improve worldwide standards 
and quality of additive manufactured products without 
any confusions126 This also enables the development of 
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Table 9. List of published ASTM standards framed by committee F04 and sub-committee IV for TEMPs.95
ASTM 
subcommittee
Category Published standards (ASTM)
F04.41 Classification and 
terminology for 
TEMPs
ASTM F2211-13 Standard specification for general classification for tissue 
engineered medical products
ASTM F2312-11(2020) Standard terminology relating to tissue engineered medical 
products
F3163-16 Standard guide for classification of cellular and/or tissue-based 
products (CTPs) for skin wounds





Standard guide for characterization and testing of raw or starting 
biomaterials for tissue engineered medical products
F2027-16 Standard guide for characterization and testing of raw or starting 
materials for tissue-engineered medical products
F2064-17 Standard guide for characterization and testing of alginates as 
starting materials intended for use in biomedical and tissue 
engineered medical product applications
F2103-18 Standard guide for characterization and testing of chitosan salts 
as starting materials intended for use in biomedical and tissue-
engineered medical product applications
F2131-02(2012) & 
WK67352
Standard test method for in vitro biological activity of recombinant 
human bone morphogenetic protein-2 (rhBMP-2) Using the W-20 
mouse stromal cell line
F2150-19 Standard guide for characterization and testing of biomaterial 




Standard guide for characterization of Type I collagen as starting 
material for surgical implants and substrates for tissue engineered 
medical products (TEMPs)
F2259-10(2012)e1 Standard test method for determining the chemical composition 
and sequence in alginate by proton nuclear magnetic resonance 
(1H NMR) spectroscopy
F2260-18 Standard test method for determining degree of deacetylation in 
chitosan salts by proton nuclear magnetic resonance (1H NMR) 
spectroscopy
F2347-15 Standard guide for characterization and testing of hyaluronan 
as starting materials intended for use in biomedical and tissue 
engineered medical product applications
F2450-18 Standard guide for assessing microstructure of polymeric scaffolds 
for use in tissue-engineered medical products
F2602-18 Standard test method for determining the molar mass of chitosan 
and chitosan salts by size exclusion chromatography with multi-
angle light scattering detection (SEC-MALS)
F2603-06(2020) Standard guide for interpreting images of polymeric tissue scaffolds
F2605-16 Standard test method for determining the molar mass of sodium 
alginate by size exclusion chromatography with multi-angle light 
scattering detection (SEC-MALS)
F2791-15 Standard guide for assessment of surface texture of non-porous 
biomaterials in two dimensions
F2952-14 Standard guide for determining the mean darcy permeability 
coefficient for a porous tissue scaffold
F3089-14 Standard guide for characterization and standardization of 
polymerizable collagen-based products and associated collagen-cell 
interactions
F3142-16 Standard guide for evaluation of in vitro release of biomolecules 
from biomaterials scaffolds for TEMPs
F3259-17 Standard guide for micro-computed tomography of tissue 
engineered scaffolds
 (Continued)
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ASTM 
subcommittee
Category Published standards (ASTM)
F3354-19 Standard guide for evaluating extracellular matrix decellularization 
processes
F3510-21 Standard guide for characterizing fiber-based constructs for tissue-
engineered medical products




F2149-16 Standard test method for automated analyses of cells—the 
electrical sensing zone method of enumerating and sizing single cell 
suspensions. document to be reviewed for possible updating of 
data evaluation section
F2315-18 Standard guide for immobilization or encapsulation of living cells or 
tissue in alginate gels
F2664-19e1 Standard guide for assessing the attachment of cells to biomaterial 
surfaces by physical methods
F2944-20 Standard practice for automated colony forming unit (CFU) 
assays—image acquisition and analysis method for enumerating and 
characterizing cells and colonies in culture
F2997-13 Standard practice for quantification of calcium deposits in 
osteogenic culture of progenitor cells using fluorescent image 
analysis
F3088-14 Standard test method for use of a centrifugation method to 
quantify/study cell-material adhesive interactions
F3106-14 Standard guide for in vitro osteoblast differentiation assays
F3206-17 Standard guide for assessing medical device cytocompatibility with 
delivered cellular therapies
F3369-19e1 Standard guide for assessing the skeletal myoblast phenotype
F3209-16 Standard guide for autologous platelet-rich plasma for use in tissue 
engineering and cell therapy
F2739-19 Standard guide for quantitating cell viability within biomaterial 
scaffolds
F04.44 Assessments for 
TEMPs
F2451-05 Standard guide for the assessment of implantable devices intended 
to repair or regenerate articular cartilage
F2529-13 Standard guide for in vivo evaluation of osteoinductive potential 
for materials containing demineralized bone (DBM)
F2884-12 Standard guide for pre-clinical in vivo evaluation of spinal fusion
F3207-17 Standard guide for in vivo evaluation of rabbit lumbar 
intertransverse process spinal fusion model
F3223-17 Standard guide for characterization and assessment of tissue 
engineered medical products (TEMPs) for knee meniscus surgical 
repair and/or reconstruction
F3224-17 Standard test method for evaluating growth of engineered cartilage 
tissue using magnetic resonance imaging
F3225-17 Standard guide for characterization and assessment of vascular 
graft tissue engineered medical products (TEMPs)
F3368-19 Standard guide for cell potency assays for cell therapy and tissue 
engineered products
F2721-09(2014) Standard guide for pre-clinical in vivo evaluation of critical size 
segmental bone defects
F04.45 Safety WK70143 (proposed) Sampling methods of tissue engineered medical products (TEMPs) 
for sterility assurance
Table 9. (Continued)
new inventions in all fields related to additive manufactur-
ing spanning from the industrial sector to medicine. ISO 
TC 261 has a group of field expertise called a working 
group such as WG 1, WG 2, WG 3, WG 4, and WG 6 for 
the development of standards for manufacturing additive 
manufactured products. Similarly, several joint groups 
have been established with different titles such as ISO/TC 
261/JG 57 “Joint ISO/TC 261-ASTM F 42 Group: Process-
specific design guidelines and standards”, ISO/TC 261/JG 
54 “Joint ISO/TC 261-ASTM F 42 Group: Fundamentals 
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of Design”, ISO/TC 261/JG 59 “Joint ISO/TC 261-ASTM 
F 42 Group: NDT for Additive Manufacturing part”, ISO/
TC 261/JG 60 “Joint ISO/TC 261-ASTM F 42 Group: 
Additive manufacturing—Non-destructive testing and 
evaluation—Standard guideline for intentionally seeding 
flaws in parts”, etc.127 However, all these established 
standards of ISO are maintained as a catalog where the 
standards are classified into different ICS (International 




Tissue product safety 
(“ISO—ISO/TC 194/
SC 1—tissue product 
safety)96
ISO 13022:2012 Medical products containing viable human cells—application of risk 
management and requirements for processing practices
ISO 22442-1:2015 Medical devices utilizing animal tissues and their derivatives—part 1: 
application of risk management
ISO 22442-2:2015 Medical devices utilizing animal tissues and their derivatives—part 2: 
controls on sourcing, collection and handling
ISO 22442-3:2007 Medical devices utilizing animal tissues and their derivatives—part 
3: validation of the elimination and/or inactivation of viruses and 








ISO 13019:2018 Tissue-engineered medical products—quantification of sulfated 
glycosaminoglycans (sGAG) for evaluation of chondrogenesis
ISO/TR 16379:2014 Tissue-engineered medical products—evaluation of anisotropic 
structure of articular cartilage using DT (diffusion tensor)—MR 
Imaging
ISO 19090:2018 Tissue-engineered medical products—bioactive ceramics—method 
to measure cell migration in porous materials
ISO/CD TS 21560.2020 General requirements of TEMPs
ISO 7198:2016 Cardiovascular implants and extracorporeal systems—vascular 
prosthesis—tubular vascular grafts and vascular patches




ISO 13405-1:2015 Prosthetics and orthotics—classification and description of 
prosthetic components—part 1: Classification of prosthetic 
components
ISO 13405-2:2015 Prosthetics and orthotics—classification and description of 
prosthetic components—part 2: Description of lower limb 
prosthetic components
ISO 13405-3:2015 Prosthetics and orthotics—classification and description of 
prosthetic components—part 3: Description of upper limb 
prosthetic components
ISO 21065:2017 Prosthetics and orthotics—terms relating to the treatment and 
rehabilitation of persons having a lower limb amputation
ISO 8549-1:2020 Prosthetics and orthotics—vocabulary—part 1: general terms for 
external limb prostheses and external orthoses
ISO 8549-2:2020 Prosthetics and orthotics—vocabulary—part 2: terms relating to 
external limb prostheses and wearers of these prostheses
ISO 8548-1:1989 Prosthetics and orthotics—limb deficiencies—part 1: method of 
describing limb deficiencies present at birth
ISO 8548-2:2020 Prosthetics and orthotics—limb deficiencies—part 2: Method of 
describing lower limb amputation stumps
ISO 8548-3:1993 Prosthetics and orthotics—limb deficiencies—part 3: Method of 
describing upper limb amputation stumps
ISO 8548-4:1998 Prosthetics and orthotics—limb deficiencies—part 4: Description of 
causal conditions leading to amputation
ISO 8548-5:2003 Prosthetics and orthotics—limb deficiencies—part 5: Description of 
the clinical condition of the person who has had an amputation
ISO 29783-1:2008 Prosthetics and orthotics—vocabulary—part 1: normal gait
ISO 29783-2:2015 Prosthetics and orthotics—vocabulary—part 2: Prosthetic gait
ISO 8549-3:2020 Prosthetics and orthotics—vocabulary—part 3: terms relating to 
orthoses
ISO 8549-4:2020 Prosthetics and orthotics—vocabulary—part 4: terms relating to 
limb amputation
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Table 11. Established ISO & ASTM standards applied for global tissue engineered product regulation from basic pre-clinical 
research to clinical trial research.
Published ISO standards Ref
ISO 14155:2020 Clinical investigation of medical devices for human subjects—
Good clinical practice
Bosiers et al.99
ISO 22442-1:2020 Medical devices utilizing animal tissues and their derivatives—
part 1: Application of risk management
ISO100
ISO 22442-2:2020 Medical devices utilizing animal tissues and their derivatives—
part 2: Controls on sourcing, collection and handling
ISO101
ISO 10993-1:2018 Biological evaluation of medical devices—part 1: evaluation and 
testing within a risk management process
Parente102
ISO 10993-2:2006 Biological evaluation of medical devices—part 2: animal welfare 
requirements
Singh et al.103
ISO 10993-3:2014 Biological evaluation of medical devices—part 3: tests for 
genotoxicity, carcinogenicity and reproductive toxicity
De Moura and  
Van Houten104
ISO 10993-7:2008/AMD 1:2019 Biological evaluation of medical devices—part 7: ethylene oxide 
sterilization residuals—amendment 1: applicability of allowable 
limits for neonates and infants
Gimeno et al.105
ISO 10993-9:2019 Biological evaluation of medical devices—part 9: framework for 
identification and quantification of potential degradation products
Reeve and Baldrick106
ISO 10993-12:2012 Biological evaluation of medical devices—part 12: sample 
preparation and reference materials
Coleman et al.107
ISO 10993-13:2010 Biological evaluation of medical devices—part 13: identification 
and quantification of degradation products from polymeric 
medical devices
Deliversky et al.108
ISO 10993-14:2001 Biological evaluation of medical devices—part 14: identification 
and quantification of degradation products from ceramics
Deliversky et al.108
ISO 10993-15:2019 Biological evaluation of medical devices—part 15: identification 
and quantification of degradation products from metals and alloys
Horicsányi et al.109
ISO 10993-18:2020 Biological evaluation of medical devices—part 18: chemical 
characterization of medical device materials within a risk 
management process
Jóźwicka et al.110
ISO 22196:2011 Measurement of antibacterial activity on plastics and other  
non-porous surfaces
Qureshi et al.111
ISO13314:2011 Mechanical testing of metals—ductility testing—compression test 
for porous and cellular metals
Zaharin et al.112
ISO 13485:2016 Medical devices—quality management systems—requirements 
for regulatory purposes
Bhat et al.89
ISO 7198:1998 Specific requirement for tubular prostheses for vascular functions Aussel et al.113
ISO 21536:2007/AMD 1:2014 Non-active surgical implants—joint replacement implants—
specific requirements for knee-joint replacement implants—
amendment 1
Marchiori et al.114
ISO 14630:2012 Non-active surgical implants—general requirements
ISO 5840-1:2015 Cardiovascular implants—cardiac valve prostheses—part 1: 
general requirements
Zhang et al.115
ISO 9001:2015 Quality management systems—requirements Bt Hj Idrus et al.16
ISO/IEC 17025:2017 General requirements for the competence of testing and 
calibration laboratories
ISO 13019:2018 Tissue-engineered medical products—quantification of sulfated 
glycosaminoglycans (sGAG) for evaluation of chondrogenesis
ISO116
ISO/TR 16379:2014 Tissue-engineered medical products—evaluation of anisotropic 
structure of articular cartilage using DT (Diffusion Tensor)-MR 
Imaging
Tensor117
ISO 19090:2018 Tissue-engineered medical products—bioactive ceramics—
method to measure cell migration in porous materials
ISO118
ISO/TS 21560:2020 General requirements of tissue-engineered medical products ISO119
 (Continued)
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Published ISO standards Ref
Active ASTM standard
ASTM F2150-19 Standard guide for characterization and testing of biomaterial 
scaffolds used in tissue-engineered medical products
Tesk93
ASTM F2211-13 Standard classification for tissue engineered medical products 
(TEMPs)
Tesk93
ASTM F2312-11 Standard terminology relating to tissue engineered medical 
products
Lee et al.72
ASTM F2739-19 Standard guide for quantitating cell viability within biomaterial 
scaffolds
Oyama et al.120
ASTM F2315-18 Standard guide for immobilization or encapsulation of living cells 
or tissue in alginate gels
Lee et al.72
ASTM F3142-16 Standard guide for evaluation of in vitro release of biomolecules 
from biomaterials scaffolds for TEMPs
Garcia et al.121
ASTM F1635-16 Standard test method for in vitro degradation testing of 




ASTM F2027-1.6 Standard guide for characterization and testing of raw or starting 
biomaterials for tissue-engineered medical products
Amato123
ASTM F2211-13 Standard classification for tissue engineered medical products 
(TEMPs).
Tesk93
ASTM F2450-18 Standard guide for assessing microstructure of polymeric 
scaffolds for use in tissue engineered medical products
Garcia et al.121




classification of standards) with specific description level 
(field, group, subgroup) with codes for better understand-
ing and followed as required.
Clinical research guidelines
International Organizations such as the World Health 
Organization, Council for International Organizations of 
Medical Sciences (CIOMS), US Department of Health 
and Human Services, National Institute of Health, 
Council of Europe and Nuffield Council on Ethics are 
working to provide guidance for the research on the 
health care field on ethics, safety and quality medical 
therapy/products development.128 The main objective is to 
ensure that guidelines should be clear, complete and 
should take into consideration of all regulatory aspects of 
the country. To ensure human health with safer medicinal 
products, several guidelines are being published in col-
laboration with a wide variety of technical experts of the 
field to provide all the detailed procedures and require-
ments with ethical concerns relevant to the particular 
topic.16 Additionally, an International standard for con-
ducting clinical trials named “Good Clinical Practice” 
was issued by International Conference on Harmonization 
(ICH).129 Furthermore, clinical trials should be conducted 
under the ethical principles in the Declaration of Helsinki, 
earlier risk and beneficial assessment, rights, safety and 
well-being of participants analysis, planned data storage 
and with approved protocols. All the published, new and 
revised versions of the guidelines for tissue engineered 
product regulation of the US, India and European Union 
are highlighted in Table 12 with a brief description of the 
guidelines and their scope. The objectives of these regula-
tions are based on providing maximum benefits with mini-
mum risk and hence EC (Ethical Committee), researchers 
and other stakeholders are always dependent on benefit-
risk assessments.129 These guidelines helps researchers, 
industrial manufacturers, marketing authorization mem-
bers and other involved members about the regulatory 
need, approach and analysis. Importantly, these guide-
lines have to be regularly revised, modified and improved 
envisaging tissue engineered product commercialization 
in the future.
On a similar note, ICMR in India formulated the first 
guidelines, “Ethical guidelines for biomedical research on 
human participants” in 2006 to conduct human trial 
research with proper safety measures and effective utiliza-
tion of study for further applications. It states to conduct 
human research with four basic principles that include per-
son’s beneficence, non-maleficence, respect and justice to 
protect participant dignity, safety, rights and wellbeing. 
Despite various ambiguity and lack of clarity in 2006 
guidelines, the following are some technical factors to be 
considered while revising in future:130
 i.  Possibility of allowing clinical trial for drugs, 
which are under approval stage by Drug controlled 
general of India (DCGI)
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  ii.  Not stated regarding the prior agreement for 
patients benefits after the study and possibility of 
patient withdrawal should be clear based on the 
study
iii.  Permission for conducting epidemiological stud-
ies on school children of age less than 18 years 
should be clear with parent’s decision
 iv.  Scientific review and approval of the proposal by 
the Institutional Ethical Committee (IEC) should 
be established
This guideline was recently revised in 2017 and renamed 
as “National Ethical Guidelines for Biomedical and 
Health Research Involving Human Participants” that cov-
ers the ethical lagging for the already existing and new 
research fields with several updates including a risk-
based approach for product categorization and with main 
considerations of resource availability.131 Further, the 
newly included sections such as Responsible Conduct of 
Research (RCR), public health research, socio-behavioral 
research, and research during humanitarian disasters and 
emergencies provide clear guidelines to all the end-users. 
This revised version helps to better understand the ethics, 
importance of research/product quality and personal 
safety for biomedical and human research.131 It has been 
made mandatory that all clinical trials conducted in India 
should be registered in Clinical Trials Registry–India 
(CTRI) (launched in 2007). Likewise, the newly estab-
lished, updated and available guidelines needed for the 
medicinal tissue-based regulation for European Union 
and US are tabulated (Table 12).
Current status toward clinical 
translation of engineered tissue 
constructs
In a recent report, it was observed that upon the interest of 
Tissue Engineered (TE) product research & development, 
there have been 66 on-going or approved TE clinical trials 
(biomaterial/stem cell) between 2011 and 2018 in the 
United States, indicating a trajectory of TE product growth 
toward clinical testing.135 The global tissue engineering 
market report 2019 had concluded that North America 
(43%) and Europe (35%) holds the largest marketing 
shares of TE products and further reported that the world-
wide tissue engineering market reached 14,000 million 
USD in 2018 and it is expected to reach 55,200 Million 
USD by 2025.136 On the other hand, bioprinted tissues 
have major obstacles toward clinical translation due to the 
degradation profile of the construct, immunogenicity of 
the bioinks, shape fidelity, durability and difficulty in the 
incorporation of vascularity and less affordability for the 
targeted applications.137,138 However, 3D bioprinted tis-
sue constructs have several advantages and are gaining 
momentum toward effective ways to overcome these 
existing challenges. As an example, the average treatment 
cost of a single burn patient would be approximately 
around $88,000, whereas large-scale production of 3D bio-
printed skin might cost less than this threshold.139 Another 
issue with the clinical practice of 3D bioprinted engineered 
tissues would be the timeline for developing matured tis-
sues or organs with respect to patients need. Specifically, 
developing simple tissues such as tubular constructs (blood 
vessels, heart valves) and skin requires a shorter time, 
whereas complex tissues or organs such as bladder, liver, 
kidneys, etc., may require longer time owing to high cell 
density, granularity, vascularization and additional time 
for tissue maturation in vitro.140 Yet several manufacturers 
are utilizing this technique for other applications such as 
cosmetics, tumor models, drug screening and discovery. 
To date, there is no single bioprinted FDA-approved prod-
uct for clinical use that is commercially available in the 
market. Organovo, a 3D bioprinting company, has suc-
cessfully bioprinted a liver tissue patch and implanted it in 
a mice model. This liver patch showed better engraftment, 
fluid retention and other liver-specific functionality for 
only up to 35 days. As a result, the manufacturer has com-
mitted to continue testing the patch further on large ani-
mals before testing on humans.141 Patient-specific tooth 
constructs (8 mm × 8 mm × 20 mm) with human dental 
pulp stem cell (hDPSCs) were printed by Jonghyeuk Han 
et al. using PCL, gelatin, hyaluronic acid, glycerol and 
fibrinogen. 5 mg/mL fibrinogen was used to mimic the 
pulp portion of teeth and 20 mg/mL of fibrinogen was used 
to print dentin in the PCL support. hDPSCs cultured in 
high concentrated fibrinogen exhibited odontogenic differ-
entiation by expressing DMP1 and DSPP markers with 
higher mineralization. In contrast, low concentrated fibrin-
ogen located in the pulp region maintained cells in the 
undifferentiated state.142 Similarly, autologous cells based 
3D printed cartilage constructs were developed by Hee-
Gyeong Yi et al. for the augmentative rhinoplasty applica-
tion using alginate and cartilage-derived ECM bioinks. 3D 
models were designed by scanning the patient face using 
FaceGen and further processing using Instep software. The 
resultant digital file was used to fabricate implants of 
38.2 mm × 7.3 mm × 6.1 mm (L × W × H) size and the 
human adipose stem cell-laden (hASC) bioink was 
injected. The constructs containing cartilage-decellular-
ized ECM showed higher expression of chondrocyte spe-
cific genes such as SOX9, ACAN, and COL21A and GAG 
at day 14 and 28 days compared to constructs with 
alginate.143 These studies showed the efficacy of 3D print-
ing and cell therapies in fabricating patient-specific mod-
els to treat patients with cartilage defects, pancreatic, heart 
problems and other major therapies in the future. However, 
more clinical trials need to do to improve the patient safety 
and efficiency of the product. Nonetheless, the engineered 
or bioprinted tissues have various ethical scrutiny while 
translating from bench/pre-clinical side to bedside, which 
Sekar et al. 25
needs to be addressed in the early stages of research 
thereby thwarting lavish expense of time and money.
Major problems in clinical transformation of 
engineered and bioprinted tissues
Worldwide regulatory considerations are not standardized 
with a common approach for the TEMPs category and 
hence there is a need for amendments in current standards 
and regulations. The technical enforcement of regulatory 
unions on framing the guidelines, reviewing and decision 
making may differ across the world based on the regula-
tory framework considered for its assessment.144 However, 
revisions in legislations and adaption of standards to the 
current technical developments are still lagging in many 
cases, thus making it a challenge for clinical translation of 
TEMPs.8 This is because the regulatory bodies take a huge 
time to comprehend the evolving transformations of new 
technologies and develop appropriate regulations/laws. 
Further, the experts of these bodies may not be able to 
make regulations by anticipating future products and tech-
nologies. However, these regulatory bodies may be advo-
cated to form a multi-disciplinary research team that 
includes scientists, legal experts and social scientists. This 
team could be a part of the regulatory from the start of the 
development of a new technology and to form suitable 
regulations. This idea is developed as RRI: Responsible 
Research and Innovation which advocates this type of 
multi-disciplinary integration from the inception of new 
products development.82
As an alternative to overcome these challenges, most 
regulatory bodies are involved in an adaptive approach for 
its approval of cellular therapy products, gene therapy 
products, tissue engineered products and additive manu-
factured medical devices. TEMPs are complex and non-
reliable products due to the incorporation of natural 
biomaterials and cells, which cause different host reactions 
to the product in a population. Thus, from a product point 
of view, scientific uncertainties of TEMPs cause a massive 
challenge and executional difficulties for regulatory 
authorities to approve medicinal therapies and products. In 
addition, most of the clinical trials have ended up with 
minimal efficiency and/or inducing high risk in patients’ 
health, thus it gets automatically rejected during the 
approval process. Nevertheless, these limitations make it 
difficult to formulate common guidelines for characteriz-
ing the material/product and it heavily affects the commer-
cialization of high-risk category products to be legally 
approved for clinical practice all over the world.15 Though 
suitable TEMPs are designed and studied well, delay in 
their market approval is due to the many different proce-
dures and licensing steps involved in the regulations. It 
includes pre-clinical assessment studies (animal model, 
efficacy study, toxicology study), clinical trial design 
(experimental group and endpoint design, GCP and GMP 
maintenance), clinical outcome and approval decision 
after risk-based quality and efficacy assessments. However, 
less availability of preclinical results adds to the chal-
lenges on approval of engineered tissue under the high-risk 
categories. In these perspectives, the major challenges 
faced by researchers, sponsors and other non-medical 
regime partners are mainly due to stringent regulations, 
poor knowledge in the requirements to conduct clinical tri-
als, inadequate laboratory practice guidelines and lack of 
funds that eventually make the clinical translation of tis-
sue-based products more difficult. Furthermore, the una-
vailability of prior relevant standards also limits most of 
the clinical trial approval of TEMPs.
A pilot study conducted by Davies et al. in the United 
Kingdom along with cardiology, neurology, ophthalmol-
ogy, orthopedic surgery, plastic and reconstructive sur-
gery clinical specialists, have identified the major barrier 
for clinical transformation as efficacy and cost-effective-
ness in addition to other observations including safety, 
regulation, methodology, visibility and patient character-
istics for cell-based therapy clinical treatment. Moreover, 
it was also noted that inconsiderate processing techniques 
involved in manufacturing reduce the possibilities of 
approval through regulatory pathways.145 In another 
study, Hanna et al. stated that the number of ATMPs 
approved clinical studies in the EU has increased every 
year from 12 to 150 numbers between 2004 and 2014. 
Among the collected data with a total of 939 clinical tri-
als, only 6.9% were in end-stage study (in phase III), 
which can take another 5 years for commercialization and 
the remaining 92.2% were in the early stages (phase I, 
combined phase I, II, and III stages). This may be due to 
the availability of sponsors (commercial/non-commer-
cial) for the study, lack of market access and launching 
strategies and financial budget.146 Culme-Seymour et al. 
studied the cost-effective way to deliver engineered 
trachea for improving the health of three patients (two 
children and one adult). A patient could undergo the 
treatment procedure with multiple charges ranging from 
US$500,000 to US$600,000 based on treatment, availa-
bility and follow-up period. It also includes clinical 
charges (related to the patient’s care at the hospital), clin-
ical testing charges (charges due to the undergone proce-
dures and analysis prior to and after treatment) and 
charges for engineered air transplant tissue and its main-
tenance. An estimated total manufacture cost for stem 
cell engineered trachea replacement is approximately 
$27,490, which could be considered as a cost-effective 
treatment in comparison with the quality of life regained 
after the treatment under severe conditions with available 
surgical procedures.147
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Ethical concerns on TEMPs, 3D 
printed and bioprinted tissues
Cell source, processing procedures and their 
cost
Complex aspects of tissue engineering and bioprinting 
make its therapeutic potential ethically complicated com-
pared to biologics and drugs.84,148 One of the major ethical 
concerns in TEMPs and bioprinted constructs is the cell 
source and its processing procedures.149 Cells and engi-
neered tissue-based therapies are considered as drugs or 
biologics in few countries like Japan and the EU union. In 
these countries, cells and engineered tissue-based thera-
pies are regulated under common legislations. In contrast, 
cell only therapy (autologous or stem cell) has different 
regulations when compared to 3D-printed/bioprinted/engi-
neered tissues in US and other countries.150–152 The human 
body has different types of cells such as stem cells, cardiac 
cells, bone cells, nerve cells, fat cells, blood cells, muscle 
cells, etc. Among these stem cells, mesenchymal and 
induced pluripotent stem cells isolated from healthy adult 
donors are widely used as cell sources in TEMPs and bio-
printed constructs due to their high differentiation poten-
tial toward any particular lineage of interest and negligible 
immunogenicity. Further, the use of embryonic stem cells 
(ESCs) isolated from blastocysts was considered unethi-
cal in some countries due to its collection procedure from 
living or aborted fetuses (either single cell or cluster of 
cells). These cells should not be intended to use for 
cloning humans, germ cells, embryos and human-animal 
chimeras.153 However, there may be limitations such as 
the large risk of patient’s compliance, less therapeutic effi-
ciency after implantation, high cost and compromised 
safety.154,155 There are several successful short-term in 
vivo studies, but long-term studies have indicated that 
these cells may lead to the risk of teratoma and cancer 
related issues.156 Numerous studies suggested that MSCs 
isolated from tissues such as the umbilical cord, bone 
marrow, adipose tissue, etc., have the potential to differ-
entiate irrepressibly, suppress the immune system and pro-
duce new blood vessels, thereby promoting tumor growth 
and metastasis.157 In a study, hMSCs were intravenously 
injected into female BALB/c 4T1 tumor induced mice 
model and showed an increase in the tumor growth and 
metastasis, TGF-beta, interleukins (IL-4, IL-10) and 
decrease in interferon-gamma production, thereby enhanc-
ing the immunosuppressive environment for 35 days.158 In 
the literature, few works reported the use of MSCs, ESCs 
and iPSCs isolated from mouse, murine, human and chicks 
as bioink components for the printing of various tissues 
such as skin, cornea, bone, heart, etc. In many reports, 
primary cells and other cell types were used for bioprint-
ing applications. For example, Michael et al. have used 
laser-assisted bioprinter and developed a cellularized skin 
substitute containing fibroblasts and keratinocytes on 
Matriderm for full-thickness wounds. The skin substitute 
was implanted in vivo and showed better integration with 
the host skin and neovascularization in the affected area 
within 11 days post-surgery.159 In another study, mesen-
chymal stromal cell lines (D1 cells) along with collagen 
and nano-hydroxyapatite were bioprinted in situ on mice 
calvaria defect model and showed enhanced bone vol-
ume to total volume using micro-CT experiments after 
2 months of treatment.160 In conclusion, most of these 
bioprinted constructs were tested in vivo for its better 
engraftment with host tissues, vascularization and regen-
eration efficiency, but these are only initial studies and 
would have to go a long way through pre-clinical and clin-
ical evaluations.
Patient-specific cells may be another choice to be used 
as a cell source for both seeding on TEMPs and bioprinting 
organs to avoid the ethical issues on cell sources. It is pos-
sible to isolate stem cells from patients with informed con-
sent, thereby providing an immediate solution for the 
shortage of organ donors and limiting the use of immuno-
suppressants.161 However, the cost of stem cell collection 
procedure, in vitro culturing and fabrication procedures 
would require GMP sophisticated laboratories, expen-
sive consumables, equipment, quality assurance testing, 
researchers, surgeons and biomedical engineers would be 
highly expensive and hence only benefits high income 
communities.162,163 Yet, customized and personalized 
products developed using the bioprinting technique may 
reduce the cost as they are 3D bioprinted on a very small 
scale.2 On the whole, 3D bioprinted organs would be 
more beneficial for the recipients waiting for donors. We 
hope that it may reduce the black market for organs or 
human transplantable materials if the cost gets reduced.164 
However, clinical translation of 3D bioprinting may be a 
huge challenge while considering the social stratification, 
global inequalities and overall cost.148 Further, implemen-
tation of this newer technology into the existing healthcare 
and insurance systems requires careful considerations.
Variability after implantation
An important facet to be considered after implantation of 
TEMPs in patients’ body is that it exhibits an inherent vari-
ability due to the dynamic response of metabolically active 
cells in the host ECM environment, which may develop 
immune rejections or mismatch within the patient’s 
body.165 In some cases, migration of the impregnated cells 
from TEMPs to other parts of the host body through the 
bloodstream may occur and this may cause unnecessary 
adverse events such as cancer or any unknown diseases. 
Some common ethical issues and risks associated with 
TEMPs are microbial contamination(re-infection), insuffi-
cient sterility and toxicity due to the presence of allogenic 
sources, dysfunction of bioactive motifs, over reactions 
of growth factors and toxicity of cryo-preservatives.166 
Further, clinical trials on 3D bioprinted tissues require a 
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more individual centric approach (transplantation medi-
cine) than conventional normal trials. For example, these 
products have to be tested in an individual subject and 
should be continued on other subjects only after evaluating 
the clinical response in the first subject.167 Furthermore, 
3D bioprinted tissue/organs could cause a high risk to the 
subject and hence such trials should be done when there is 
no alternative option for the chosen subject.
Ownership of products
Finally, the ownership of products or bioprinted organs 
would be an issue for the donors, recipients, researchers, 
doctors and product manufacturing companies. A few 
known issues are (i) the donors must be informed about the 
future and further applications of their donated stem cells; 
(ii) safety issues related to the blueprint of patient’s organ 
since advancement in genetic engineering may develop a 
cloned organs or simple biological building blocks (though 
it may take several decades to commence) and (iii) the 
owner of developed product for a patent will be an issue 
either for researcher, patient or company.165
Conclusion
Fabrication of personalized living tissues/organs is now 
more possible and realistic with the approaches in 
3D-bioprinting. In spite of the availability of adaptive reg-
ulations, only a very few TEMPs have been licensed. Even 
though scientific requirements and pre-clinical standards 
are constantly revised, several tissue engineered products 
and 3D bioprinted tissues are yet to enter clinical trials. 
This could be attributed to the fact that the current legisla-
tion and standards are more suited for conventional drugs/
therapeutics and therefore fails to fully absorb the com-
plexities involved in the latest medicinal products. Hence, 
it is imperative for the regulatory authorities and other par-
ties to learn the background of these advanced products 
and adapt the complexities to facilitate the approval pro-
cesses for TEMPs and 3D bioprinted tissues. Further, the 
clinicians and researchers should learn the scientific 
requirements, background of standards, necessary training 
on clinical trials and GMPs to fulfill the needs of regula-
tory bodies and global standards. In conclusion, consider-
ing the nature of TEMPs and 3D bioprinted tissues, it is 
essential to make sure that the products are within shelf-
life time at the time of clinical procedure and tested with 
well-planned protocols to assess the safety and long-term 
efficacy.
Future perspectives
In order to anticipate the future of 3D bioprinting, it is 
imperative to understand the current advancements 
achieved in the successful development of 3D bioprinted 
tissues such as skin, cartilage and bone. This achievement 
is due to the clinically most relevant features attained in 
printing these constructs such as suitable cell types, 
desired functional aspects, biomimetic resolution and 
other required associated cues, including vascular net-
work. Therefore, successfully 3D bioprinted skin, carti-
lage and bone could serve as a yardstick to envision the 
future prospects and commercialization scope of fabri-
cated constructs.
Figure 4 shows the 3D bioprinted tissues/organs, and 
bioprinted organ-on-chip developments along with antici-
pated years for regulatory approval and commercializa-
tion. On considering the medical device, ISO and other 
regulations in force, we anticipate that bioprinted 3D tis-
sue models and organ-on-chip may not undergo stringent 
regulations and hence could be envisaged for commercial-
ization possibilities in the next 5–8 years. In contrary, com-
mercialization chances for 3D bioprinted tissues and 
organs are anticipated only in the forthcoming decades due 
to complex nature and multiple biological compositions. 
Additionally, a collaborative approach between academia, 
industry and hospitals is needed to draw regulatory amend-
ments, which could further improve the clinical translation 
of bioprinted organs/tissue.
Despite the benefits of creating fully functional soft and 
hard 3D tissues with neovascularization ability, additional 
challenges include culturing the printed heterogeneous tis-
sues/organs with a different supporting medium in a biore-
actor or with any special set up for maturation. Further, the 
highest possible printing resolution with a laser bioprinter 
is 20 µm while small capillaries of native tissues are 3 μm 
in diameter. In addition to the small diameter, the complex-
ity of vascular networks with the multi-level organization 
is yet to be achieved in 3D bioprinting. Other challenges 
are the requirement of a huge number of cells for printing, 
the need for extensive research on optimal bioink compo-
sition with good printing capabilities, shape fidelity and 
the demand for sophisticated advanced complementary 
bioprinting technologies with ensured environment and 
sterility maintenance. Additionally, bioprinting has several 
other difficulties such as ethical issues, safety, affordabil-
ity, and large-scale production for successful translation 
into clinical practice. Marketing approval for the bio-
printed tissue equivalents is yet to be achieved with the 
current/revised legislation and hence focus is needed 
toward these directions to utilize 3D bioprinting for the 
fabrication of organs for transplantation needs. As a next-
generation fabrication approach, the 4D bioprinting con-
cept with an additional ability of printed constructs to 
undergo complete maturation in response to dynamic 
external stimuli may be followed. In the future, several 
extensive researches on smart bioink composition with 
excellent shape fidelity, feasibility for large scale produc-
tion, potential bioprinters and faster clinical trials for the 
developed bioprinted constructs will definitely pave the 
28 Journal of Tissue Engineering 
way for clinical success and commercialization scope as 
compared to conventional TEMPs.
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